Caroline Mitchell, MD
Obstetrics & Gynecology · Boston, MANPI 1063442788
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,178 of the $4,240 with a category attached, or 98.5%. Ferring Pharmaceuticals Inc. accounts for 65.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $4,178 and has fallen 99.4% since, to $24 in 2024. Among obstetrics & gynecology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 5 payments — averaging $847.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$3K
- Scynexis, Inc.$1K
- GSK$39
- Astellas Pharma US Inc$24
Across 11 payments — averaging $26,228 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$277K
- Scynexis, Inc.$12K
What the payments were for
- Consulting fees$4,17899%
- Food & beverage$621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 1 | $2,778 |
| Scynexis, Inc. | 1 | $1,400 |
| GSK | 2 | $39 |
| Astellas Pharma US Inc | 1 | $24 |
How this compares
$4,240 in reported general payments places this provider in the 90th percentile of 910 obstetrics & gynecology providers in Massachusetts.
See all obstetrics & gynecology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 32 | $2,275 |
| Tacrolimus | 13 | $1,446 |
| Fluconazole | 20 | $125 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Boston
- Elizabeth OnyemelukweBoston$135K
- James GreenbergBoston$119K
- Stephanie AlimenaBoston$75K
- Denis VaughanBoston$38K
- Roxanne GardnerBoston$31K
- Marc LauferBoston$23K
- Michelle LightfootBoston$23K
- Paul HendessiBoston$18K
- Marcus OrtegaBoston$17K
- Elizabeth GagliardiBoston$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.